Overall Survival Benefit and Long-Term Safety of Romiplostim in Persistent Chemotherapy-Induced Thrombocytopenia

• by Andrew B. Song, Gerald A. Soff

• September 28, 2026

Correction: Lessons Learned From Implementing a Culturally Tailored Virtual Support Program for Asian American Breast Cancer Survivors With Pain and Depression

• by Seulgi Ryu, Dongmi Kim, Wonshik Chee, Eun-Ok Im

• September 25, 2026

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

• by Paul J. Hampel, Ying Huang, John N. Allan, Seema A. Bhat, David Bond, Danielle M. Brander, John C. Byrd, Julio C. Chavez, Elise Chong, Alexey Danilov, Matthew S. Davids, Kaitlyn Dvorak-Kornaus, Hannah Freedman, Nikita Malakhov, Matthew Matasar, Cecelia Miller, Sarah Miller, Zulfa Omer, Sameer A. Parikh, Erin M. Parry, Kari G. Rabe, Phil Raess, Manoj Rai, Joanna M. Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Geoffrey Shouse, Stephen Spurgeon, Deborah Stephens, Yucai Wang, Jennifer A. Woyach, Max Yano, Adam S. Kittai

• September 26, 2026

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

• by

• September 24, 2026

• 11 min